SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMNR - Immune Response
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Andrew H who wrote (1237)1/12/1999 5:31:00 PM
From: jake burns  Read Replies (1) of 1510
 
I expect that imnr and its collaborative partner will embark on a ph2c trial which will not involve patients on prednisone. And then of course a ph3 will follow. I understand the segment that wasn't on prednisone was a Mark McGwire home run. So what's another 6-12 months in the scheme of things? Unless Imnr gets bought out this stock should languish in the 10 dollar range until the nda gets filed for remune in the 2H99. Although I believe IMNR will get bought out by Agouron, the Street sure as hell doesn't as this stock is acting like crap.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News